PRLD — Prelude Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $38.70m
- -$94.71m
- $7.00m
- 23
- 38
- 43
- 27
Annual cashflow statement for Prelude Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -56.9 | -112 | -115 | -122 | -127 |
| Depreciation | |||||
| Non-Cash Items | 5.59 | 23.6 | 29.5 | 24.1 | 18.3 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 4.62 | 3.63 | 0.932 | -10.5 | 4.22 |
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Cash from Operating Activities | -46.2 | -83.5 | -83.7 | -107 | -103 |
| Capital Expenditures | -0.621 | -2.32 | -3.02 | -3.51 | -0.764 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | — | -261 | 84.7 | -31.1 | 91 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -0.621 | -264 | 81.7 | -34.6 | 90.2 |
| Financing Cash Flow Items | -0.012 | -0.303 | 0 | -0.017 | -0.164 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 246 | 165 | 0.815 | 136 | -0.12 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 199 | -182 | -1.22 | -5.31 | -12.8 |